Product Results

Fibrosis

Fibrosis is a pathogenic response to chronic inflammation that includes an excess of extracellular matrix (ECM) deposition and tissue stiffening, which can lead to organ dysfunction, morbidity, and death. A variety of stimuli including infection, autoimmune reactions, toxins, radiation, and mechanical injury can cause fibrosis. Unfortunately, the mechanisms which cause fibrosis are not well understood and present a major challenge to effectively treat the disease. Cell Signaling Technology (CST) and our expert scientists help to provide high-quality, validated antibodies and products in support of your research into fibrosis.

Antibodies Signaling Pathway in Fibrosis

When developing therapeutics, it is important to understand the signaling pathways that contribute to the activation and maintenance of fibrotic cells such as myofibroblasts. CST offers a variety of validated antibodies to probe key fibrotic pathways to support your discovery research.

Antibodies for Metabolism in Fibrosis

Metabolic changes are associated with fibrosis in a variety of organ types. Cell Signaling Technology (CST) offers a diverse selection of validated antibodies to advance the discovery and development of novel treatments targeting fibrotic metabolism.

Antibodies to Immune Response in Fibrosis

Although the relationship between inflammation and fibrosis is deeply interconnected and has many overlapping mechanisms, the interplay between them is poorly understood. CST offers a wide variety of antibodies that can support your research into the immune-driven aspects of fibrosis pathogenesis.

Antibodies to Extracellular Matrix Proteins

Extracellular matrix (ECM) is essential for normal tissue and cellular function and plays a role in differentiation, metabolism, proliferation, however, excessive accumulation can drive the progression of fibrosis. CST offers a diverse catalog of validated antibodies to better understand ECM proteins in support of your fibrosis research.

Antibodies to Cell Death in Fibrosis

There is increasing evidence that cell death can contribute to fibrosis at several stages - initiation, progression, and resolution of disease. CST provides validated antibodies to reliably measure cell death and the underlying mechanisms of fibrosis.

Antibodies to Tumor Microenvironment in Fibrosis

Fibrotic tissue in the tumor microenvironment (TME) supports cancer progression, survival, and metastasis. CST offers a diverse selection of antibodies to interrogate the architecture of the TME.

Antibodies to Cytoskeletal Proteins

During fibrosis, activation of fibroblasts to become myofibroblasts is marked by changes in the cellular cytoskeleton. Activated fibroblasts are characterized by the expression of alpha smooth actin and the deposition of excessive collagens, fibronectin, and other components into the ECM. The validated and reliable antibodies offered by CST can be used to probe the proteins involved in the underlying changes of pro-fibrotic cells.

Assays and Kits

Assessing fibrotic activity by measuring collagen content and signaling molecules provides important information to advance the discovery of novel therapeutic targets. CST has reliable, time-saving assays to measure changes in protein expression and signaling to help advance fibrotic discovery research.